On Monday, Denali Therapeutics Inc (NASDAQ: DNLI) opened higher 4.04% from the last session, before settling in for the closing price of $23.02. Price fluctuations for DNLI have ranged from $14.56 to $25.24 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 264.19%. Company’s average yearly earnings per share was noted -143.80% at the time writing. With a float of $119.04 million, this company’s outstanding shares have now reached $138.39 million.
The extent of productivity of a business whose workforce counts for 445 workers is very important to gauge. In terms of profitability, gross margin is 102.8%, operating margin of 163.02%, and the pretax margin is 138.14%.
Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Denali Therapeutics Inc is 16.85%, while institutional ownership is 84.65%. The most recent insider transaction that took place on Aug 13 ’24, was worth 52,006. In this transaction COFO and Secretary of this company sold 2,272 shares at a rate of $22.89, taking the stock ownership to the 186,419 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Chief Medical Officer sold 2,337 for $22.89, making the entire transaction worth $53,494. This insider now owns 141,268 shares in total.
Denali Therapeutics Inc (DNLI) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -143.80% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Check out the current performance indicators for Denali Therapeutics Inc (DNLI). In the past quarter, the stock posted a quick ratio of 12.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2699.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.85, a number that is poised to hit -0.62 in the next quarter and is forecasted to reach -2.57 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
The latest stats from [Denali Therapeutics Inc, DNLI] show that its last 5-days average volume of 0.79 million was inferior to 1.16 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 89.10%. Additionally, its Average True Range was 1.18.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 87.92%, which indicates a significant increase from 76.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.41% in the past 14 days, which was lower than the 54.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.44, while its 200-day Moving Average is $19.80. Now, the first resistance to watch is $24.45. This is followed by the second major resistance level at $24.94. The third major resistance level sits at $25.75. If the price goes on to break the first support level at $23.15, it is likely to go to the next support level at $22.34. The third support level lies at $21.85 if the price breaches the second support level.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are currently 142,609K shares outstanding in the company with a market cap of 3.43 billion. Presently, the company’s annual sales total 330,530 K according to its annual income of -145,220 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -99,030 K.
